Is Aristada Approved for Bipolar Disorder?
No, Aristada (aripiprazole lauroxil) is FDA-approved only for schizophrenia in adults. It is a long-acting injectable atypical antipsychotic that helps manage symptoms like hallucinations and delusions in schizophrenia patients.[1]
Why Not for Bipolar—What's the Difference?
Aristada's oral counterpart, Abilify (aripiprazole), is approved for bipolar I disorder (manic or mixed episodes, maintenance). Aristada, however, lacks this approval due to its extended-release formulation, which targets schizophrenia specifically. No FDA nod exists for bipolar use.[1][2]
Can Doctors Prescribe It Off-Label for Bipolar?
Yes, physicians may prescribe Aristada off-label for bipolar based on aripiprazole's established efficacy there. Some psychiatrists use it for maintenance in bipolar I, especially for non-adherent patients, citing similar pharmacology. Evidence is limited to case studies and extrapolation—no large trials support it.[3]
How Does Aristada Compare to Bipolar Treatments?
| Treatment | Approved For | Dosing | Key Notes |
|-----------|--------------|--------|-----------|
| Aristada | Schizophrenia | Monthly/6-week IM injection | Prodrug converts to aripiprazole slowly; black box warning for elderly dementia risk. |
| Abilify Maintena (aripiprazole) | Schizophrenia, bipolar I | Monthly IM injection | Direct bipolar approval; similar profile to Aristada. |
| Vraylar (cariprazine) | Bipolar I (manic/mixed/depressive) | Daily oral | Partial agonist like aripiprazole; broader bipolar coverage. |
| Latuda (lurasidone) | Bipolar depression | Daily oral | Often paired with lithium/valproate. |
Aristada offers convenience over daily pills but lacks bipolar-specific data, so Maintena is preferred for that indication.[1][4]
Common Side Effects and Bipolar Patient Concerns
Patients report weight gain, akathisia (restlessness), sedation, and injection-site pain. For bipolar, risks include metabolic changes worsening mood instability. Long-acting nature means side effects linger—switching takes weeks. Monitor for tardive dyskinesia.[1][2]
When Might Aristada Get Bipolar Approval?
No ongoing trials or FDA filings for bipolar as of now. Patents on Aristada expire around 2030, opening biosimilar paths, but expansion seems unlikely without new data.[5]
[1]: FDA Label for Aristada
[2]: Abilify Prescribing Information
[3]: Off-Label Use Review in CNS Drugs
[4]: Drugs.com Comparison
[5]: DrugPatentWatch.com - Aristada Patents